Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma — Michael S. Khodadoust (2020) | RDL Network
Edward R. Scheffer Cliff, Thomas E. Lew, Piers Blombery, Michael Dickinson, Constantine S. Tam, John F. Seymour, Ashish Bajel, David Ritchie, Amit Khot
Pier Luigi Zinzani, Tatyana Feldman, Graham P. Collins, Jasmine Zain, Amit Khot, J. S. Kim, Franck Morschhauser, T. M. Kim, Justine E. Roderick, Jeong Lim Yoon, Shringi Sharma, Jamal Saeh, Jianrong Dai, R. Reyes, Richard F. Olsson, Jake Shortt
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Véronique Leblond, Béatrice Mahé, Charles Herbaux, Jeffrey Matous, Constantine S. Tam, Leonard T. Heffner, Marzia Varettoni, M Lia Palomba, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jerry Ping, Bernhard Hauns, Israel Arango‐Hisijara, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.